Sector Expert: Patrick Dolezal
"Highlights of DRRX's second quarter include reaching a commercialization agreement with Sandoz, completing enrollment of a pivotal Phase III trial for this asset, and completing drug-drug interaction studies and a Phase Ib trial for DUR-928."
Patrick Dolezal, LifeSci Advisors
"DRRX is a biopharmaceutical company with a rich development pipeline that includes an epigenetic regulator program and a portfolio of 505(b)(2) programs."
Patrick Dolezal, LifeSci Capital